Journal of medicinal chemistry · 2026
Discovery and Optimization of a Potent, Efficacious, and Brain-Penetrant Inhibitor of KRAS G12C.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Landry Matthew L, Malhotra Sushant, Beresini Maureen, Chan Connie, Chan Emily, de la Cruz Cecile C, Endres Nicholas F, Evangelista Marie, Gustafson Amy, Hu Dennis, Hunsaker Thomas, Hsu Peter, Izrayelit Yevgeniy, La Hank, Saenz-Lopez Larrocha Pablo, Lian Qihui, Merchant Mark, Mao Jialin, Mroue Rana, Oh Angela, Plise Emile, Shao Cheng, Siu Michael, Tran John C, Wang Yanguang, Wang Weiru, Wei Binqing, Wong Susan, Yen Chun-Wan, Zhou Yuhui, Purkey Hans E, Heffron Timothy P, Salphati Laurent
Аннотация
Mutant KRAS is highly prevalent in human cancer and has been actively pursued as a target for drug discovery. Much progress has been made in drugging KRAS G12C, owing to the ability of inhibitors to covalently target its oncogenic cysteine mutation at codon 12. A number of KRAS G12C inhibitors have advanced to clinical development and are being investigated for the treatment of a variety of solid tumors. Notably, many patients with KRAS G12C-positive non-small cell lung cancer develop brain metastases. Herein, we report the discovery and development of a brain-penetrant inhibitor of KRAS G12C using divarasib as a starting point. Optimization efforts focused on reducing molecular weight and topological polar surface area as well as shielding of hydrogen bond donors. In this manner, active transport by both P-gp and breast cancer resistance protein (BCRP) was attenuated, and high exposure in rodent brain tissue was achieved.